Methotrexate resistant cells at targets for selective chemotherapy

J. R. Bertino, E. Mini, A. Sobrero, B. A. Moroson, T. Love, M. Jastreboff, M. Carmen, S. Srimatkandada, S. Dube

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Strategies that are selective for eradicating methotrexate resistant cells are described. These strategies have been developed based on knowledge of the mechanism of drug resistance encountered in experimental systems and in the clinic. Drug resistance to methotrexate in experimental tumors is commonly due to either gene amplification (dihydrofolate reductase) or to impaired transport of methotrexate. While no effective drugs or methods to prevent gene amplification have been described, the concept of developing "pro drugs", i.e. a drug that is selectively reduced by dihydrofolate reductase to an inhibitor of another critical folate enzyme (thymidylate synthase, methionine synthetase, folylpolyglutamte synthetase) remains worthwhile. Second generation antifolates such as trimetrexate which are effective vs methotrexate transport resistant cells have already been developed and are in clinical trial.

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalAdvances in Enzyme Regulation
Issue numberC
StatePublished - 1985
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Methotrexate resistant cells at targets for selective chemotherapy'. Together they form a unique fingerprint.

Cite this